Below are links to research studies in cancer. If you are thinking of taking part in one, please talk to your doctor.

• A phase II/III trial of primary radiotherapy for androgen sensitive prostate cancer patients with lymph nodes (PEARLS)

• A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer.

• A study to assess if treatment with Camizestrant improves outcome of early breast cancer compared with standard endocrine treatment

• A study to evaluate the effectiveness of BNT113 in combination with Pembrolizumab in treatment of Head & Neck Squamous cell carcinoma

• A study to test whether a package of Personalised Prehabilitation improves how patients cope with Acute Myeloid Leukaemia treatment

• A trial to evaluate the use of 3 combined drugs in treatment of acute myeloid leukaemia

• ACCoRd Trial MyELOMA XII - A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with Relapsed multiple myeloma.

• ADePT-DDR Trial - Accelerating the Development and implementation of Personalised Treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer

• ALLTogether1 - ALLTogether1 – A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

• An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B cell Malignancies

• Assess the safety and efficacy of using Volrustomig in treatment of locally advanced head and neck cancer

• Assessing the use of antifungal medication during acute Leukemia treatment versus ongoing blood test monitoring for fungal infections

• ATNEC - A trial looking at further treatment to the armpit after surgery to remove breast cancer

• ARIEL - A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL)

• aTTom-Extended: Extended follow-up of patients enrolled in the Adjuvant Tamoxifen Treatment - Offer More? (aTTom) trial.

• Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery - ARTEMIS

• Breast Screening survey to evaluate moving to a risk based approach to screening

• BRIOChe - A trial giving radiotherapy again for glioblastoma

• CheckMate73L - A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

• Chemotherapy Induced Cognitive Impairment CONCERT

• Childrens Cancer and Leukaemia Group (CCLG) Tissue Bank (2018 BS 03)

• CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia) - A randomised trial to assess the use of ciprofloxacin prophylaxis to prevent bacterial infection in children treated on the induction phase of the ALLTogether1 treatment protocol

• Co-Designing Digitally Enhanced Cancer Aftercare

• Comparing Two Surgical methods for removal of Sarcomas

• Corinth - A trial looking if pembrolizumab can safely be added to chemo-radiotherapy for patients with anal cancer

• Determining impact of the composition of the Oral and Faecal Microbiota on the response of Patients with RectalCancer to therapy before Surgery. MicrobRect

• Developing Tests to prevent Liver injury due to Checkpoint Inhibitor drugs

• E²-RADIatE (EORTC 1811)

• Effectiveness of dietary fibre supplementation in early Prostrate Cancer

• EndoNET - Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women

• Evaluating the effectiveness of Ginisortamab in treatment of metastatic pancreatic ductal adenocarcinoma

• Evaluation of different imaging-guided methods in breast cancer lesion removal

• EvoPAR-Prostate01 - A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305in Combination with Physician’s Choice New Hormonal Agents in Patients withHRRm and non-HRRm Metastatic Castration‑Sensitive Prostate Cancer (EvoPAR-Prostate01)

• Exploiting the gut microbiota and its metabolites in pelvic cancer to improve patient outcomes (PELICAN-23)

• Fast Field Cycling MRI and microbiota in Rectal Cancer

• HPV Equity Study: exploring cervical cancer control in Scotland for women with experience of priority risks

• The Commands trial - A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions

• Development of a decision aid for parents

• E²-RADIatE (EORTC 1811)

• Evaluate the Efficacy and Safety of Tafasitamab plus Lenalidomide in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

• EXCALIBER-Maintenance - A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly DiagnosedMultiple Myeloma (NDMM) (EXCALIBER-Maintenance)

• Exploring physical activity in young adults with cancer

• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

• FIERCE-HN - A trial FICLATUZUMAB in combination with CETUXIMAB in patients with Head and Neck cancer that has spread or came back.

• FITNEsS - A trial of ixazomib, lenalidomide and dexamethasone for people with myeloma

• frontMIND - Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

• Fruquintinib in Patients With Metastatic Colorectal Cancer

• GARNET - A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.

• Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA

• GENPROS - Analysing outcomes after prostate cancer diagnosis and treatment in carriers of rare germline mutations in cancer predisposition genes.

• Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

• Health Seeking Behaviour in Women Diagnosed With Gynaecological Cancer: Can it be Modified to Improve Patient Outcomes?

• High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

• HoT - Hemithyroidectomy or Total-Thyroidectomy in 'low-risk' thyroid cancers

• Hypoxia PET/CT in Lung Carcinoma

• ICONIC - Improving outcomes through collaboration in osteosarcoma

• IHCAP - Investigating Hereditary Cancer Predisposition a combined genomics approach.

• IMPORT / UMBRELLA - Improving Population Outcomes for Renal Tumours of Childhood applying PMedicine tools to improve treatment decisions for Wilms tumour and other renal tumours of childhood and young adults: A SIOP Renal Tumours Study Group prospective clinical study.

• IMerge - Imetelstat in Myelodysplastic syndrome (MDS)

• Investigating a new joint approach to treating metastatic bone disease: radiotherapy first?

• ISA101b - A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive Oropharyngeal Cancer (OPC)

• KEYNOTE 866 - A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

• Keynote 991 - Phase 3 study of pembrolizumab/placebo + Enzalutamide + ADT in metastatic hormone sensitive prostate cancer

• Kidney Cancer - Comparing 2 Surgical Approaches

• LCH-IV - International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis.

• LEAP-008 - A trial of pembrolizumab and lenvatinib for people who have had treatment for non small cell lung cancer (LEAP-008)

• LIMBER-304 - A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib inParticipants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

• M15-954:Venetoclax and/or Azacitidine in Newly Diagnosed High-Risk MDS

• MajesTEC-9 - A Phase 3 Randomized Study in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy

• MDS registry for newly diagnosed patients

• MITHRIDATE - A trial comparing ruxolitinib with best available treatment for polycythaemia vera

• MOSAICC Study - MyelOproliferative neoplasmS: An In-depth Case-Control (MOSAICC) study: A case-control study of patients with Myeloproliferative neoplasms and non-blood relative/friend controls

• NCCPG TDM 2018 A Clinical Pharmacology Study to Investigate the Utility of Therapeutic Drug Monitoring in Challenging Childhood Cancer Patient Populations

• OPTIMA - Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis

• Olympia-2 - A study comparing an experimental drug called odronextamab in combination with chemotherapy to standard of care in patients with previously untreated follicular lymphoma

• PARADIGM - Plasma analysis for response assessment and to direct the management of metastatic prostate cancer

• Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice.

• Pembrolizumab & Chemoradiation in Oesophageal Carcinoma Participants

• PETNECK 2: PET-CT guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head and neck cancer

• PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma

• PIONEER Grampian Electronic Health Record Pilot Project

• PIONEER WP2 What outcomes are important for patients with advanced prostate cancer?

• PRECISION-Panc - Advancing personalised medicine treatment strategies for pancreatic cancer.

• Preoperative tattooing of biopsied axillary node in breast cancer

• PRIMUS-001 - An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation.

• PRiZM+: A phase II platform study of zanubrutinib monotherapy and combination therapy for relapsed and refractoryprimary CNS lymphom

• PROTECTOR - Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal

• RADAR - A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma

• RADAR (UK-MRA Myeloma XV)

• Rad-IO - A trial of chemoradiotherapy and durvalumab for invasive bladder cancer

• Radiomics in Rectal Cancer: A Retrospective Study

• RAMPART - Renal Adjuvant MultiPle Arm Randomised Trial: An international investigator-led phase III multi-arm multistage randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.

• READ-RISK - Towards Early Detection of Breast Cancer in High Risk Population

• rEECur - International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.

• REFRACT - Relapsed Follicular lymphoma Randomised trial Against standard ChemoTherapy (REFRACT): A randomised phase II trial of investigator choice standard therapy versus sequential novel therapy experimental arms

• Repurposed drugs to improve haematological responses in Myelodysplastic Syndromes (REPAIR-MDS)

• Researching the Effect of Fat Cells in development of Cancer and Metabolic Disorders

• Secured Access to innovative medicines for CHildren, adolescents and young adults with cAncer (SACHA)

• SIOP Ependymoma II - International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma

• SIOP - PNET 5 - A study looking at improving treatment for children and young people with medulloblastoma

• Sleep Therapy in newly diagnosed Breast Cancer Patients

• SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer – a phase III randomised multi-centre trial

• Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia (SAVER)

• STATIC v1.0 - A Randomised Phase III Trial Comparing Intermittent with Continuous Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)

• Trial of drug LY3537982 in treatment of Non Small Cell Lung Cancer

• Trialling the use of digital technologies in aftercare to prompt and support self care for melanoma patients in remote and rural areas

• Trialling use of additional Medicinal Product for brain tumour

• OLYMPIA-3 - A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab REGN1979, an anti-CD20 × antiCD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

• Photographic Rhinometry following Derm/Mohs Surgery for Skin Cancers

• The UK National Registry of Chronic Myeloid Leukaemia (CML)

• Tracking mutations in cell free tumour DNA to predict Relapse in eArly Colorectal Cancer

• The SCOTTY Study - whole genome sequencing study of young colon cancer patients and their parents

• The role of circulating tumour DNA in head and neck cancer

• UK - P3BEP - A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

• VICTOR -Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 Study

• VOLUME-PRO - niVOLUMab in the rEal world in patients with squamous cell carcinoma of the head & neck (SCCHN) – Patient Reported Outcomes (PRO)

• Phase3 pembro+chemoradiation +/- olaparib vs chemoradiation in LS-SCLC